OncoSignal
Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:56 UTC. Every row links to its source record.

Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time

Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications

NCT05827614 · Boundless Bio, Inc. · PHASE1 · terminated · last registry update 2026-08-19 · Non-small cell lung cancer · Decision brief

No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.

What was said, and by whom

Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.

KindQuoteOur categorySource
Stated“Decision was made to halt the study based on overall clinical experience and market considerations. This decision was not driven by any safety signal.”–Registry record, Boundless Bio, Inc.

Also happening at the time. Not shown to be a cause.

Registry events on other trials of drugs against EGFR in non-small cell lung cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.

What is not public

  • Internal portfolio and board discussions
  • Unpublished trial data and interim analyses
  • Terms of any partner or licence decision